Alpha Cognition Revenue
Pharmaceutical Manufacturing • 
Vancouver, British Columbia, Canada • 51-100 Employees
Alpha Cognition revenue & valuation
| Annual revenue | $4,452,562 |
| Revenue per employee | $75,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Pharmaceutical Manufacturing industry and current estimated revenues | $14,300,000 |
| Total funding | $83,600,000 |
Key Contacts at Alpha Cognition
Michael Mcfadden
Chief Executive Officer
Trierre Shanks
Regional Business Director Ltc
Phillip Mertz
Director
Stephanie Mcallister
Director, Access And Reimbursement
Jennifer Lane-Watson
Regional Business Director
Jack Kelly
Executive Director, Head Of Market Access
Michael Spence
Regional Business Director
Greg Anderson
Regional Business Director
Tom Tobin
Executive Director, Market Access
Andrew Wahlert
Director, Medical Affairs
Company overview
| Headquarters | 439 Helmcken Street, Vancouver, B.C. V6B 2E6, CA |
| Phone number | +18583444375 |
| Website | |
| NAICS | 3254 |
| SIC | 283 |
| Employees | 51-100 |
| Socials |
Alpha Cognition Email Formats
Alpha Cognition uses 3 email formats. The most common is {first name}{last name} (e.g., johndoe@alphacognition.com), used 49% of the time.
| Format | Example | Percentage |
|---|---|---|
{first name}{last name} | johndoe@alphacognition.com | 49% |
{first initial}{last name} | jdoe@alphacognition.com | 35.3% |
{last name}{last name} | doedoe@alphacognition.com | 15.7% |
About Alpha Cognition
Alpha Cognition is a clinical stage, biopharmaceutical company dedicated to developing novel treatments for under-served neurodegenerative diseases such as Alzheimer’s Dementia and Amyotrophic Lateral Sclerosis (ALS). ALPHA-1062, a patented new chemical entity that has demonstrated safety and improved tolerability in human clinical trials. It is being developed as a new acetylcholine esterase inhibitor for the treatment of dementia of the Alzheimer’s type, with minimal gastrointestinal side-effects and novel routes of administration. ALPHA-0602 is a gene therapy program delivering progranulin, a neurotrophic protein. It is in preclinical development for the treatment of ALS. ALPHA-0602 is patented and has received Orphan Drug Designation from the FDA.
Employees by Management Level
Total employees: 51-100
Seniority
Employees
Employees by Department
Alpha Cognition has 41 employees across 9 departments.
Departments
Number of employees
Funding Data
Explore Alpha Cognition's funding history, including investment rounds, total capital raised, and key backers.
Alpha Cognition Tech Stack
Discover the technologies and tools that power Alpha Cognition's digital infrastructure, from frameworks to analytics platforms.
CDN
Font scripts
Web servers
Security
JavaScript libraries
Tag managers
Hosting
JavaScript libraries
Security
Font scripts
Miscellaneous
Video players
Germany
Netherlands
Indonesia
Philippines
Frequently asked questions
4.8
40,000 users
